Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $279.5 million.

  • Apellis Pharmaceuticals' Total Current Liabilities rose 46.15% to $279.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.5 million, marking a year-over-year increase of 46.15%. This contributed to the annual value of $185.5 million for FY2024, which is 25.08% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Total Current Liabilities stood at $279.5 million for Q3 2025, which was up 39.30% from $200.7 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Total Current Liabilities' 5-year high stood at $279.5 million during Q3 2025, with a 5-year trough of $83.7 million in Q1 2021.
  • In the last 3 years, Apellis Pharmaceuticals' Total Current Liabilities had a median value of $185.6 million in 2023 and averaged $197.0 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Total Current Liabilities spiked by 172.09% in 2021 and then dropped by 25.08% in 2024.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Total Current Liabilities stood at $131.8 million in 2021, then grew by 27.12% to $167.6 million in 2022, then surged by 47.72% to $247.6 million in 2023, then declined by 25.08% to $185.5 million in 2024, then skyrocketed by 46.15% to $279.5 million in 2025.
  • Its last three reported values are $279.5 million in Q3 2025, $200.7 million for Q2 2025, and $178.4 million during Q1 2025.